ClinicalTrials.gg
Active, not recruitingNCT04524273MINTUpdated May 15, 2026Results posted

Myasthenia Gravis Inebilizumab Trial

A Phase 3 interventional study of inebilizumab and IV Placebo in Myasthenia Gravis, sponsored by Amgen. Active, not recruiting at 104 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
238
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Enrollment
4th of 108
238 · median 56
Started
2020
with 3 others
Phase 3
45 of 144
9 open now
Primary completion
2024-05
later than 2 of 72 live
Registered
55th of 144
by date
Lead sponsor
2 of 144
Amgen

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 4th largest by enrollment of the 108 interventional ones that give a count, is one of 4 that started in 2020, is one of 45 in phase 3, reaches primary completion later than 2 of the 72 other live ones, and was the 55th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.

Read the detailed description

This study is a phase 3, randomized, double-blind, placebo-controlled study, to be conducted at approximately 120 study sites. Approximately 230 participants (188 acetylcholine receptor antibody positive [AChR-Ab+] and 42 muscle-specific tyrosine kinase antibody positive [MuSK-Ab+]) will be enrolled. Participants with Myasthenia Gravis (MG) who are positive for anti-AChR or anti-MuSK antibodies will be enrolled and analyzed. Patients who do not have anti-AChR or anti-MuSK antibodies will not be enrolled. Patients with Myasthenia Gravis Foundation of America (MGFA) classification II, III, or IV disease, Myasthenia Gravis Activities of Daily Living (MG-ADL) score at screening and randomization between 6 and 10 with > 50% of this score attributed to non-ocular items, or an MG-ADL score >=11, Quantitative Myasthenia Gravis (QMG) score >= 11 at the time of screening and randomization, and use of a corticosteroid and/or non-steroidal immunosuppressant will be included in the study.

All subjects who complete the randomized controlled period (RCP) will have the option to enroll in a 3-year (156 weeks) open-label period.

Study acquired from Horizon in 2023.

03

Conditions studied

  • Myasthenia Gravis

Browse trials for

Keywords

  • Myasthenia Gravis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of MG with anti-AChR or anti-MuSK antibody.
  2. MGFA Clinical Classification Class II, III, or IV.
  3. MG-ADL score of 6 or greater at screening and at randomization with > 50% of this score attributed to non-ocular items.
  4. QMG score of 11 or greater.
  5. Participants must be on:

    1. only, with no dose increase within 4 weeks prior to randomization, or
    2. One allowed non-steroidal therapy (IST), with continuous use for at least 6 months prior to randomization and no dose increase within 4 months prior to randomization, or
    3. Combination of (1) corticosteroids with no dose increase within 4 weeks prior to randomization and (2) one allowed non-steroidal IST with continuous use for at least 6 months prior to randomization and no dose increase within 4 months prior to randomization.

Allowed ISTs, alone or in combination with corticosteroids, are azathioprine, mycophenolate mofetil, and mycophenolic acid.

Exclusion criteria

Exclusion Criteria:

  1. Receipt of the following medications within the 4 weeks prior to Day 1:

    1. Cyclosporine (except eye drops)
    2. Tacrolimus (except topical)
    3. Methotrexate
  2. Current use of:

    1. (Prednisone > 40 milligram (mg)/day or > 80 mg over a 2-day period (or equivalent dose of other corticosteroids).
    2. Acetylcholinesterase inhibitors (pyridostigmine) > 480 mg/day) or unstable dose in the 2 weeks prior to Day 1.
    3. Azathioprine > 3 mg/kilogram (kg)/day
    4. Mycophenolate mofetil > 3 grams/day or mycophenolic acid > 1440 mg/day
    5. Any IST, alone or in combination with corticosteroids, except for azathioprine, mycophenolate mofetil, and mycophenolic acid.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
238 participants (actual)

Study arms

  • Experimental
    Inebilizumab, (AChR-Ab+) MG

    Participants will receive inebilizumab administered intravenously (IV) on Days 1, 15, and 183 of the RCP. Participants who elect to enter the open label phase (OLP) will receive inebilizumab administered IV on OLP Days 1, IV placebo on OLP Day 15 (to avoid potential unblinding), and inebilizumab IV on OLP Days 183, 365, 547, 729, and 911.

    Drug: inebilizumab

  • Placebo comparator
    Placebo, (AChR-Ab+) MG

    Participants will receive placebo administered IV on Days 1, 15, and 183 of the RCP. Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Days 1,15, 183, 365, 547, 729, and 911.

    Drug: IV Placebo

  • Experimental
    Inebilizumab, (MuSK-Ab+) MG

    Participants will receive inebilizumab administered IV on Days 1 and 15 of the RCP. Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Day 1, IV placebo on OLP Day 15 (to avoid potential unblinding), and inebilizumab IV on OLP Days 183, 365, 547, 729, and 911.

    Drug: inebilizumab

  • Placebo comparator
    Placebo, (MuSK-Ab+) MG

    Participants will receive placebo administered IV on Days 1 and 15 of the RCP. Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Days 1,15, 183, 365, 547, 729, and 911.

    Drug: IV Placebo

Interventions

  • Participants will receive IV inebilizumab

    Also known as: MEDI-551, VIB0551

  • DrugIV Placebo

    Participants will receive IV placebo matched to inebilizumab

06

What researchers measure

Primary outcomes

  1. Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population

    MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease Outcome measure is reported for the overall population.

    Time frame: Baseline and Week 26

Secondary outcomes

  1. Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score at Week 26 in the Overall Study Population

    The QMG score is a validated outcome comprised of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item has a possible score of between 0 and 3 points. The total score range is 0-39 points, with higher score indicating more severe disease. Outcome measure is reported for the overall population.

    Time frame: Baseline and Week 26

  2. Change From Baseline at Week 26 in MG-ADL Score in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

    MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: Baseline and Week 26

  3. Change From Baseline in QMG Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

    The QMG score is a validated outcome comprised of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item has a possible score of between 0 and 3 points. The total score range is 0-39 points, with higher score indicating more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: Baseline and Week 26

  4. Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in the Overall Study Population

    MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. The protocol-allowed rescue therapy options included intravenous immunoglobulin (IVIg) and therapeutic plasma exchange (PLEX). Outcome measure is reported for the overall population.

    Time frame: Up to Week 26

  5. Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

    MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. The protocol-allowed rescue therapy options included IVIg and PLEX. Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: Up to Week 26

  6. Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 52 and no Use of Rescue Therapy Between Day 28 and Week 52 in Anti-AChR-Ab+ Population

    MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. The protocol-allowed rescue therapy options included IVIg and PLEX. Outcome measure is reported for the Anti-AChR-Ab+ population.

    Time frame: Up to Week 52

  7. Percentage of Participants With no Use of Rescue Therapy Between Day 28 and Week 52 in Anti-AChR-Ab+ Population

    The protocol-allowed rescue therapy options included corticosteroids, IVIg and PLEX. Outcome measure is reported for the Anti-AChR-Ab+ population.

    Time frame: Up to Week 52

  8. Change From Baseline in MG-ADL Score at Week 52 in the Anti-AChR-Ab+ Population

    MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ population.

    Time frame: Baseline and Week 52

  9. Change From Baseline in QMG Score at Week 52 in the Anti-AChR-Ab+ Population

    The QMG score is a validated outcome comprised of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item has a possible score of between 0 and 3 points. The total score range is 0-39 points, with higher score indicating more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ population.

    Time frame: Baseline and Week 52

  10. Change From Baseline in Myasthenia Gravis Composite (MGC) Score at Week 26 in the Overall Study Population

    The MGC score consists of test items from MG-ADL score and the QMG score, with weighted response options. Scores range from 0-50, with higher scores indicating worse disease manifestations. Outcome measure is reported for the overall population.

    Time frame: Baseline and Week 26

  11. Change From Baseline in MGC Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

    The MGC score consists of test items from MG-ADL score and the QMG score, with weighted response options. Scores range from 0-50, with higher scores indicating worse disease manifestations. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: Baseline and Week 26

  12. Change From Baseline in MGC Score at Week 52 in Anti-AChR-Ab+ Population

    The MGC score consists of test items from MG-ADL score and the QMG score, with weighted response options. Scores range from 0-50, with higher scores indicating worse disease manifestations. Outcome measure is reported for the Anti-AChR-Ab+ population.

    Time frame: Baseline and Week 52

  13. Change From Baseline in Myasthenia Gravis Quality of Life-15, Revised (MGQOL-15r) Score at Week 26 in the Overall Study Population

    MGQOL-15r score is a validated, patient-scored instrument, which measures the impact of MG on health-related quality of life (HRQoL). The 15 items in the questionnaire evaluate mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items) domains. Each item is rated on a 3-point scale ranging from 0 ("not at all") to 2 ("very much") based on their experience "over the past few weeks." Items scores are summed to generate a total score ranging from 0-45, with higher score indicating worse HRQoL. Outcome measure is reported for the overall population.

    Time frame: Baseline and Week 26

  14. Change From Baseline in MGQOL-15r Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

    MGQOL-15r score is a validated, patient-scored instrument, which measures the impact of MG on health-related quality of life (HRQoL). The 15 items in the questionnaire evaluate mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items) domains. Each item is rated on a 3-point scale ranging from 0 ("not at all") to 2 ("very much") based on their experience "over the past few weeks." Items scores are summed to generate a total score ranging from 0-45, with higher score indicating worse HRQoL. Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: Baseline and Week 26

  15. Change From Baseline in MGQOL-15r Score at Week 52 in Anti-AChR-Ab+ Population

    MGQOL-15r score is a validated, patient-scored instrument, which measures the impact of MG on health-related quality of life (HRQoL). The 15 items in the questionnaire evaluate mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items) domains. Each item is rated on a 3-point scale ranging from 0 ("not at all") to 2 ("very much") based on their experience "over the past few weeks." Items scores are summed to generate a total score ranging from 0-45, with higher score indicating worse HRQoL. Outcome Measure is reported for the Anti-AChR-Ab+ population.

    Time frame: Baseline and Week 52

  16. Percentage of Participants With Patient Global Impression of Change (PGIC) Scores at Week 26 in the Overall Study Population

    The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a participant's rating of overall improvement. Participant rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse", Outcome measure is reported for the overall population.

    Time frame: Week 26

  17. Percentage of Participants With PGIC Scores at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

    The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a participant's rating of overall improvement. Participants rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse". Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: Week 26

  18. Percentage of Participants With PGIC Scores at Week 52 in Anti-AChR-Ab+ Population

    The self-report measure PGIC score reflects a participant's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a participant's rating of overall improvement. participants rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse". Outcome measure is reported for the Anti-AChR-Ab+ population.

    Time frame: Week 52

  19. Percentage of Participants Experiencing Exacerbation by Week 26 in the Overall Study Population

    An exacerbation was defined as one of the following: * Use of protocol defined rescue therapy, or * Myasthenic crisis, defined as worsening of myasthenic weakness requiring intubation or non-invasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management, or * Significant symptomatic worsening to a score of 3 or a 2-point worsening from baseline on any one of the individual MG-ADL items other than double vision or eyelid droop. Outcome measure is reported for the overall population.

    Time frame: Up to Week 26

  20. Percentage of Participants Experiencing Exacerbation by Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

    An exacerbation was defined as one of the following: * Use of protocol defined rescue therapy, or * Myasthenic crisis, defined as worsening of myasthenic weakness requiring intubation or non-invasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management, or * Significant symptomatic worsening to a score of 3 or a 2-point worsening from baseline on any one of the individual MG-ADL items other than double vision or eyelid droop. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: Up to Week 26

  21. Percentage of Participants Experiencing Exacerbation by Week 52 in Anti-AChR-Ab+ Population

    An exacerbation was defined as one of the following: * Use of protocol defined rescue therapy, or * Myasthenic crisis, defined as worsening of myasthenic weakness requiring intubation or non-invasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management, or * Significant symptomatic worsening to a score of 3 or a 2-point worsening from baseline on any one of the individual MG-ADL items other than double vision or eyelid droop. Outcome measure is reported for the Anti-AChR-Ab+ population.

    Time frame: Up to Week 52

  22. Percentage of Participants Achieving Minimal Symptom Expression (MSE) at Week 26

    MSE was defined as MG-ADL= 0 or 1. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK+ populations.

    Time frame: From Day 28 to Week 26

  23. Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in the Overall Study Population

    Outcome measure is reported for the overall population.

    Time frame: Week 26

  24. Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

    Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: Week 26

  25. Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 52 in Anti-AChR-Ab+ Population

    Outcome measure is reported for the Anti-AChR-Ab+ population.

    Time frame: Week 52

  26. Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Overall Study Population

    Outcome measure is reported for the overall population.

    Time frame: Week 26

  27. Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

    Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: Week 26

  28. Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 52 in the Anti-AChR-Ab+ Population

    Outcome measure is reported for the Anti-AChR-Ab+ population.

    Time frame: Week 52

  29. Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs), AE of Special Interest (AESIs) and Serious TEAEs (SAEs).

    An AE is any untoward medical occurrence associated with the use of the IP, whether or not it is considered related. Clinically significant changes from baseline in clinical laboratory results, vital signs and ECGs were also reported as AEs. An AESI is an event of medical interest specific to the understanding of the IP and which may require close monitoring and collection of additional information. A SAE is considered "serious" if it results in any of the following outcomes: * Death; * A life-threatening AE. An event is considered "life-threatening" if its occurrence places the patient or subject at immediate risk of death; * Inpatient hospitalization or prolongation of existing hospitalization; * A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; * A congenital anomaly/birth defect; * May require medical or surgical intervention to prevent one of the outcomes listed in this definition.

    Time frame: For RCP AE reporting: from Day 1 to the end of RCP or cutoff date (up to 65.4 weeks)

  30. Percentage of Participants With Anti-drug Antibodies (ADA) by Week 26 in the Overall Study Population

    Treatment emergent ADA were defined as ADA positive post-baseline only or boosted pre-existing ADA titer. Outcome measure is reported for the overall population.

    Time frame: From Baseline to Week 26

  31. Percentage of Participants With ADA by Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

    Treatment emergent ADA were defined as ADA positive post-baseline only or boosted pre-existing ADA titer. Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: From Baseline to Week 26

  32. Percentage of Participants With ADA by Week 52 in Anti-AChR-Ab+ Population

    Treatment emergent ADA were defined as ADA positive post-baseline only or boosted pre-existing ADA titer. Outcome measure is reported for the Anti-AChR-Ab+ population.

    Time frame: From Baseline to Week 52

  33. Time to Maximum Serum Concentration (Tmax) of Inebilizumab in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

    On inebilizumab dosing days, inebilizumab pharmacokinetic (PK) serum samples were collected pre-dose and approximately 15 minutes (± 5 minutes) after completion of the IP infusion. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: Days 1 and 15 for Anti-MuSK-Ab+ population; Days 1, 15 and 183 (Week 26) for Anti-AChR-Ab+ population

  34. Maximum Observed Serum Concentration (Cmax) of Inebilizumab in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

    On inebilizumab dosing days, inebilizumab PK serum samples were collected pre-dose and approximately 15 minutes (± 5 minutes) after completion of the IP infusion. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: Days 1 and 15 for Anti-MuSK-Ab+ population; Days 1, 15 and 183 (Week 26) for Anti-AChR-Ab+ population

  35. Area Under the Serum Concentration Time Curve of the Dosing Interval (AUC0-14d) of Inebilizumab

    On inebilizumab dosing days, inebilizumab PK serum samples were collected pre-dose and approximately 15 minutes (± 5 minutes) after completion of the IP infusion. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

    Time frame: Days 1 and 15 for Anti-MuSK-Ab+ population; Days 1, 15 and 183 (Week 26) for Anti-AChR-Ab+ population

07

Results

Posted Mar 10, 2026

Participant flow

A total of 238 participants were enrolled in 18 countries, from 15 October 2020. This study is ongoing. Data cut-off date for primary analysis was 28 May 2024.

RCP
Participant flow — RCP
MilestoneAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mg
Started95952424
Completed68752324
Not completed272010
Withdrew: Adverse event0100
Withdrew: Death2100
Withdrew: Lack of efficacy1000
Withdrew: Lost to follow-up0100
Withdrew: Progressive disease2000
Withdrew: Protocol deviation1000
Withdrew: Withdrawal by subject6210
Withdrew: Miscellaneous1000
Withdrew: Ongoing at primary analysis data cut-off141500
Optional OLP
Participant flow — Optional OLP
MilestoneAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mg
Started62702224
Completed1103
Not completed61692221
Withdrew: Ongoing at primary analysis data cut-off48581510
Withdrew: Miscellaneous8655
Withdrew: Withdrawal by subject3315
Withdrew: Protocol violation1000
Withdrew: Physician decision0100
Withdrew: Lost to follow-up0001
Withdrew: Death0100
Withdrew: Adverse event1010

Outcome measures

SecondaryChange From Baseline in Quantitative Myasthenia Gravis (QMG) Score at Week 26 in the Overall Study Population

The QMG score is a validated outcome comprised of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item has a possible score of between 0 and 3 points. The total score range is 0-39 points, with higher score indicating more severe disease. Outcome measure is reported for the overall population.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score at Week 26 in the Overall Study Population
Score on a scaleOverall: PlaceboOverall: Inebilizumab 300 mg
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score at Week 26 in the Overall Study Population-2.3 (-3.4 to -1.3)-4.8 (-5.8 to -3.8)
Statistical analysis
  • Overall: Placebo vs Overall: Inebilizumab 300 mg · Mixed-effects model for repeated measure · p = 0.0002 (Based on difference in mean change. Covariates of treatment group, baseline antibody status and steroid use, baseline QMG and MG-ADL, visits, interaction between visit and treatment group.) · Difference in mean change: -2.5 · 95% CI -3.8 to -1.2
SecondaryChange From Baseline at Week 26 in MG-ADL Score in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Score on a scale
Change From Baseline at Week 26 in MG-ADL Score in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
Score on a scaleAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mg
Change From Baseline at Week 26 in MG-ADL Score in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations-2.4 (-3.2 to -1.6)-4.2 (-5.0 to -3.4)-1.7 (-3.1 to -0.2)-3.9 (-5.3 to -2.4)
Statistical analysis
  • Anti-AChR-Ab+: Placebo vs Anti-AChR-Ab+: Inebilizumab 300 mg · Mixed-effects model for repeated measure · p = 0.0015 (Based on difference in mean change. Covariates of treatment group, baseline antibody status and steroid use, baseline QMG and MG-ADL, visits, interaction between visit and treatment group.) · Difference in mean change: -1.8 · 95% CI -2.9 to -0.7
  • Anti-MuSK-Ab+: Placebo vs Anti-MuSK-Ab+: Inebilizumab 300 mg · Mixed-effects model for repeated measure · p = 0.0297 (Based on difference in mean change. Covariates of treatment group, baseline antibody status and steroid use, baseline QMG and MG-ADL, visits, interaction between visit and treatment group.) · Difference in mean change: -2.2 · 95% CI -4.2 to -0.2
SecondaryChange From Baseline in QMG Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

The QMG score is a validated outcome comprised of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item has a possible score of between 0 and 3 points. The total score range is 0-39 points, with higher score indicating more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Score on a scale
Change From Baseline in QMG Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
Score on a scaleAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mg
Change From Baseline in QMG Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations-2.0 (-3.1 to -0.9)-4.4 (-5.5 to -3.3)-3.0 (-5.2 to -0.7)-5.2 (-7.4 to -3.0)
Statistical analysis
  • Anti-AChR-Ab+: Placebo vs Anti-AChR-Ab+: Inebilizumab 300 mg · Mixed-effects model for repeated measure · p = 0.0011 (Based on difference in mean change. Covariates of treatment group, baseline antibody status and steroid use, baseline QMG and MG-ADL, visits, interaction between visit and treatment group.) · Difference in mean change: -2.5 · 95% CI -3.9 to -1.0
  • Anti-MuSK-Ab+: Placebo vs Anti-MuSK-Ab+: Inebilizumab 300 mg · Mixed-effects model for repeated measure · p = 0.1326 (Based on difference in mean change. Covariates of treatment group, baseline antibody status and steroid use, baseline QMG and MG-ADL, visits, interaction between visit and treatment group.) · Difference in mean change: -2.3 · 95% CI -5.3 to 0.7
SecondaryPercentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in the Overall Study Population

MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. The protocol-allowed rescue therapy options included intravenous immunoglobulin (IVIg) and therapeutic plasma exchange (PLEX). Outcome measure is reported for the overall population.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in the Overall Study Population
ParticipantsOverall: PlaceboOverall: Inebilizumab 300 mg
Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in the Overall Study Population5579
SecondaryPercentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. The protocol-allowed rescue therapy options included IVIg and PLEX. Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
ParticipantsAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mg
Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations44621117
SecondaryPercentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 52 and no Use of Rescue Therapy Between Day 28 and Week 52 in Anti-AChR-Ab+ Population

MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. The protocol-allowed rescue therapy options included IVIg and PLEX. Outcome measure is reported for the Anti-AChR-Ab+ population.

Time frame:
Up to Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With no Use of Rescue Therapy Between Day 28 and Week 52 in Anti-AChR-Ab+ Population

The protocol-allowed rescue therapy options included corticosteroids, IVIg and PLEX. Outcome measure is reported for the Anti-AChR-Ab+ population.

Time frame:
Up to Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline in MG-ADL Score at Week 52 in the Anti-AChR-Ab+ Population

MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ population.

Time frame:
Baseline and Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline in QMG Score at Week 52 in the Anti-AChR-Ab+ Population

The QMG score is a validated outcome comprised of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item has a possible score of between 0 and 3 points. The total score range is 0-39 points, with higher score indicating more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ population.

Time frame:
Baseline and Week 52

Results for this outcome have not been posted.

SecondaryChange From Baseline in Myasthenia Gravis Composite (MGC) Score at Week 26 in the Overall Study Population

The MGC score consists of test items from MG-ADL score and the QMG score, with weighted response options. Scores range from 0-50, with higher scores indicating worse disease manifestations. Outcome measure is reported for the overall population.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Myasthenia Gravis Composite (MGC) Score at Week 26 in the Overall Study Population
Score on a scaleOverall: PlaceboOverall: Inebilizumab 300 mg
Change From Baseline in Myasthenia Gravis Composite (MGC) Score at Week 26 in the Overall Study Population-4.7 (-6.3 to -3.1)-7.3 (-8.9 to -5.8)
SecondaryChange From Baseline in MGC Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

The MGC score consists of test items from MG-ADL score and the QMG score, with weighted response options. Scores range from 0-50, with higher scores indicating worse disease manifestations. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Score on a scale
Change From Baseline in MGC Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
Score on a scaleAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mg
Change From Baseline in MGC Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations-3.8 (-5.5 to -2.2)-6.4 (-8.0 to -4.8)-5.7 (-9.3 to -2.1)-8.3 (-11.9 to -4.8)
SecondaryChange From Baseline in MGC Score at Week 52 in Anti-AChR-Ab+ Population

The MGC score consists of test items from MG-ADL score and the QMG score, with weighted response options. Scores range from 0-50, with higher scores indicating worse disease manifestations. Outcome measure is reported for the Anti-AChR-Ab+ population.

Time frame:
Baseline and Week 52

Results for this outcome have not been posted.

PrimaryChange From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population

MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease Outcome measure is reported for the overall population.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Score on a scale
Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population
Score on a scaleOverall: PlaceboOverall: Inebilizumab 300 mg
Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population-2.2 (-3.0 to -1.5)-4.2 (-4.9 to -3.4)
Statistical analysis
  • Overall: Placebo vs Overall: Inebilizumab 300 mg · Mixed-effects model for repeated measure · p = <0.0001 (Based on difference in mean change. Covariates of treatment group, baseline antibody status and steroid use, baseline QMG and MG-ADL, visits, interaction between visit and treatment group.) · Difference in mean change: -1.9 · 95% CI -2.9 to -1.0
SecondaryChange From Baseline in Myasthenia Gravis Quality of Life-15, Revised (MGQOL-15r) Score at Week 26 in the Overall Study Population

MGQOL-15r score is a validated, patient-scored instrument, which measures the impact of MG on health-related quality of life (HRQoL). The 15 items in the questionnaire evaluate mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items) domains. Each item is rated on a 3-point scale ranging from 0 ("not at all") to 2 ("very much") based on their experience "over the past few weeks." Items scores are summed to generate a total score ranging from 0-45, with higher score indicating worse HRQoL. Outcome measure is reported for the overall population.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Myasthenia Gravis Quality of Life-15, Revised (MGQOL-15r) Score at Week 26 in the Overall Study Population
Score on a scaleOverall: PlaceboOverall: Inebilizumab 300 mg
Change From Baseline in Myasthenia Gravis Quality of Life-15, Revised (MGQOL-15r) Score at Week 26 in the Overall Study Population-4.5 (-5.9 to -3.1)-5.7 (-7.1 to -4.4)
SecondaryChange From Baseline in MGQOL-15r Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

MGQOL-15r score is a validated, patient-scored instrument, which measures the impact of MG on health-related quality of life (HRQoL). The 15 items in the questionnaire evaluate mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items) domains. Each item is rated on a 3-point scale ranging from 0 ("not at all") to 2 ("very much") based on their experience "over the past few weeks." Items scores are summed to generate a total score ranging from 0-45, with higher score indicating worse HRQoL. Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
Baseline and Week 26
Reported as:
Least squares mean · Score on a scale
Change From Baseline in MGQOL-15r Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
Score on a scaleAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mg
Change From Baseline in MGQOL-15r Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations-3.6 (-5.0 to -2.2)-4.9 (-6.3 to -3.5)-5.1 (-8.5 to -1.7)-6.5 (-9.7 to -3.3)
SecondaryChange From Baseline in MGQOL-15r Score at Week 52 in Anti-AChR-Ab+ Population

MGQOL-15r score is a validated, patient-scored instrument, which measures the impact of MG on health-related quality of life (HRQoL). The 15 items in the questionnaire evaluate mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items) domains. Each item is rated on a 3-point scale ranging from 0 ("not at all") to 2 ("very much") based on their experience "over the past few weeks." Items scores are summed to generate a total score ranging from 0-45, with higher score indicating worse HRQoL. Outcome Measure is reported for the Anti-AChR-Ab+ population.

Time frame:
Baseline and Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Patient Global Impression of Change (PGIC) Scores at Week 26 in the Overall Study Population

The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a participant's rating of overall improvement. Participant rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse", Outcome measure is reported for the overall population.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Percentage of Participants With Patient Global Impression of Change (PGIC) Scores at Week 26 in the Overall Study Population
ParticipantsOverall: PlaceboOverall: Inebilizumab 300 mg
Very Much Improved715
Much Improved2448
Minimally Improved3923
No Change1515
Minimally Worse97
Much Worse53
Very Much Worse30
SecondaryPercentage of Participants With PGIC Scores at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a participant's rating of overall improvement. Participants rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse". Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Percentage of Participants With PGIC Scores at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
ParticipantsAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab: PlaceboAnti-MuSK-Ab: Inebilizumab 300 mg
Very Much Improved41233
Much Improved1736712
Minimally Improved322073
No Change131421
Minimally Worse8314
Much Worse5201
Very Much Worse2010
SecondaryPercentage of Participants With PGIC Scores at Week 52 in Anti-AChR-Ab+ Population

The self-report measure PGIC score reflects a participant's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a participant's rating of overall improvement. participants rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse". Outcome measure is reported for the Anti-AChR-Ab+ population.

Time frame:
Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Experiencing Exacerbation by Week 26 in the Overall Study Population

An exacerbation was defined as one of the following: * Use of protocol defined rescue therapy, or * Myasthenic crisis, defined as worsening of myasthenic weakness requiring intubation or non-invasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management, or * Significant symptomatic worsening to a score of 3 or a 2-point worsening from baseline on any one of the individual MG-ADL items other than double vision or eyelid droop. Outcome measure is reported for the overall population.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Percentage of Participants Experiencing Exacerbation by Week 26 in the Overall Study Population
ParticipantsOverall: PlaceboOverall: Inebilizumab 300 mg
Percentage of Participants Experiencing Exacerbation by Week 26 in the Overall Study Population4119
SecondaryPercentage of Participants Experiencing Exacerbation by Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

An exacerbation was defined as one of the following: * Use of protocol defined rescue therapy, or * Myasthenic crisis, defined as worsening of myasthenic weakness requiring intubation or non-invasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management, or * Significant symptomatic worsening to a score of 3 or a 2-point worsening from baseline on any one of the individual MG-ADL items other than double vision or eyelid droop. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Percentage of Participants Experiencing Exacerbation by Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
ParticipantsAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mg
Percentage of Participants Experiencing Exacerbation by Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations3016113
SecondaryPercentage of Participants Experiencing Exacerbation by Week 52 in Anti-AChR-Ab+ Population

An exacerbation was defined as one of the following: * Use of protocol defined rescue therapy, or * Myasthenic crisis, defined as worsening of myasthenic weakness requiring intubation or non-invasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management, or * Significant symptomatic worsening to a score of 3 or a 2-point worsening from baseline on any one of the individual MG-ADL items other than double vision or eyelid droop. Outcome measure is reported for the Anti-AChR-Ab+ population.

Time frame:
Up to Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving Minimal Symptom Expression (MSE) at Week 26

MSE was defined as MG-ADL= 0 or 1. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK+ populations.

Time frame:
From Day 28 to Week 26
Reported as:
Count of participants · Participants
Percentage of Participants Achieving Minimal Symptom Expression (MSE) at Week 26
ParticipantsAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+:Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+:Inebilizumab 300 mg
Percentage of Participants Achieving Minimal Symptom Expression (MSE) at Week 2681833
SecondaryPercentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in the Overall Study Population

Outcome measure is reported for the overall population.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in the Overall Study Population
ParticipantsOverall: PlaceboOverall: Inebilizumab 300 mg
Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in the Overall Study Population7783
SecondaryPercentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
ParticipantsAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mg
Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations64671316
SecondaryPercentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 52 in Anti-AChR-Ab+ Population

Outcome measure is reported for the Anti-AChR-Ab+ population.

Time frame:
Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Overall Study Population

Outcome measure is reported for the overall population.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Overall Study Population
ParticipantsOverall: PlaceboOverall: Inebilizumab 300 mg
Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Overall Study Population6157
SecondaryPercentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
ParticipantsAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mg
Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations49471210
SecondaryPercentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 52 in the Anti-AChR-Ab+ Population

Outcome measure is reported for the Anti-AChR-Ab+ population.

Time frame:
Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs), AE of Special Interest (AESIs) and Serious TEAEs (SAEs).

An AE is any untoward medical occurrence associated with the use of the IP, whether or not it is considered related. Clinically significant changes from baseline in clinical laboratory results, vital signs and ECGs were also reported as AEs. An AESI is an event of medical interest specific to the understanding of the IP and which may require close monitoring and collection of additional information. A SAE is considered "serious" if it results in any of the following outcomes: * Death; * A life-threatening AE. An event is considered "life-threatening" if its occurrence places the patient or subject at immediate risk of death; * Inpatient hospitalization or prolongation of existing hospitalization; * A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; * A congenital anomaly/birth defect; * May require medical or surgical intervention to prevent one of the outcomes listed in this definition.

Time frame:
For RCP AE reporting: from Day 1 to the end of RCP or cutoff date (up to 65.4 weeks)
Reported as:
Count of participants · Participants
Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs), AE of Special Interest (AESIs) and Serious TEAEs (SAEs).
ParticipantsAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mg
TEAEs70771719
AESIs171576
SAEs15812
SecondaryPercentage of Participants With Anti-drug Antibodies (ADA) by Week 26 in the Overall Study Population

Treatment emergent ADA were defined as ADA positive post-baseline only or boosted pre-existing ADA titer. Outcome measure is reported for the overall population.

Time frame:
From Baseline to Week 26
Reported as:
Count of participants · Participants
Percentage of Participants With Anti-drug Antibodies (ADA) by Week 26 in the Overall Study Population
ParticipantsOverall: PlaceboOverall: Inebilizumab 300 mg
Percentage of Participants With Anti-drug Antibodies (ADA) by Week 26 in the Overall Study Population21
SecondaryPercentage of Participants With ADA by Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

Treatment emergent ADA were defined as ADA positive post-baseline only or boosted pre-existing ADA titer. Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
From Baseline to Week 26
Reported as:
Count of participants · Participants
Percentage of Participants With ADA by Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
ParticipantsAnti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mg
Percentage of Participants With ADA by Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations1110
SecondaryPercentage of Participants With ADA by Week 52 in Anti-AChR-Ab+ Population

Treatment emergent ADA were defined as ADA positive post-baseline only or boosted pre-existing ADA titer. Outcome measure is reported for the Anti-AChR-Ab+ population.

Time frame:
From Baseline to Week 52

Results for this outcome have not been posted.

SecondaryTime to Maximum Serum Concentration (Tmax) of Inebilizumab in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

On inebilizumab dosing days, inebilizumab pharmacokinetic (PK) serum samples were collected pre-dose and approximately 15 minutes (± 5 minutes) after completion of the IP infusion. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
Days 1 and 15 for Anti-MuSK-Ab+ population; Days 1, 15 and 183 (Week 26) for Anti-AChR-Ab+ population
Reported as:
Median · day
Time to Maximum Serum Concentration (Tmax) of Inebilizumab in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
dayAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: Inebilizumab 300 mg
Day 10.080 (0.066 to 0.10)0.081 (0.073 to 0.090)
Day 150.080 (0.0 to 17)0.080 (0.073 to 0.10)
Day 1830.078 (0.052 to 0.12)—
SecondaryMaximum Observed Serum Concentration (Cmax) of Inebilizumab in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations

On inebilizumab dosing days, inebilizumab PK serum samples were collected pre-dose and approximately 15 minutes (± 5 minutes) after completion of the IP infusion. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
Days 1 and 15 for Anti-MuSK-Ab+ population; Days 1, 15 and 183 (Week 26) for Anti-AChR-Ab+ population
Reported as:
Geometric mean · ug/mL
Maximum Observed Serum Concentration (Cmax) of Inebilizumab in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
ug/mLAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: Inebilizumab 300 mg
Day 1108 ± 30112 ± 23
Day 15120 ± 38159 ± 19
Day 183107 ± 22—
SecondaryArea Under the Serum Concentration Time Curve of the Dosing Interval (AUC0-14d) of Inebilizumab

On inebilizumab dosing days, inebilizumab PK serum samples were collected pre-dose and approximately 15 minutes (± 5 minutes) after completion of the IP infusion. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.

Time frame:
Days 1 and 15 for Anti-MuSK-Ab+ population; Days 1, 15 and 183 (Week 26) for Anti-AChR-Ab+ population
Reported as:
Geometric mean · ug*day/mL
Area Under the Serum Concentration Time Curve of the Dosing Interval (AUC0-14d) of Inebilizumab
ug*day/mLAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: Inebilizumab 300 mg
Day 1848 ± 27919 ± 25
Day 151010 ± 401350 ± 18
Day 1831060 ± 24—

Adverse events

Collected over For RCP mortality reporting: from randomization to the end of RCP or cutoff date; median (min, max) was 52.0 (2.4, 65.4) weeks. For RCP AE reporting: from Day 1 to the end of RCP or cutoff date; median (min, max) was 52.0 (2.4, 65.4) weeks. For OLP mortality and AE reporting: from the 1st dose of IP in OLP to the end of OLP or cutoff date; median (min, max) was 66.4 (0.1, 137.3) weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RCP: Placebo2/119 (1.7%)16/119 (13.4%)47/119 (39.5%)
RCP: Inebilizumab 300 mg1/119 (0.8%)10/119 (8.4%)53/119 (44.5%)
Optional OLP: Inebilizumab 300 mg1/178 (0.6%)14/178 (7.9%)40/178 (22.5%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventRCP: PlaceboRCP: Inebilizumab 300 mgOptional OLP: Inebilizumab 300 mg
COVID-19Infections and infestations3/1192/1191/178
Myasthenia gravis crisisNervous system disorders3/1192/1190/178
COVID-19 pneumoniaInfections and infestations1/1192/1193/178
PneumoniaInfections and infestations0/1190/1193/178
Acute myocardial infarctionCardiac disorders0/1190/1192/178
Anaemia megaloblasticBlood and lymphatic system disorders1/1190/1190/178
PancytopeniaBlood and lymphatic system disorders1/1190/1190/178
Atrial fibrillationCardiac disorders1/1190/1190/178
Cardio-respiratory arrestCardiac disorders1/1190/1190/178
Coronary artery stenosisCardiac disorders1/1190/1190/178
Most frequent other events
Most frequent other events
EventRCP: PlaceboRCP: Inebilizumab 300 mgOptional OLP: Inebilizumab 300 mg
HeadacheNervous system disorders8/11918/1194/178
COVID-19Infections and infestations9/11912/11910/178
DiarrhoeaGastrointestinal disorders8/1194/1191/178
NasopharyngitisInfections and infestations3/1198/1198/178
Urinary tract infectionInfections and infestations3/1198/1192/178
ArthralgiaMusculoskeletal and connective tissue disorders8/1195/1191/178
CoughRespiratory, thoracic and mediastinal disorders4/1198/1198/178
HypertensionVascular disorders8/1192/1192/178
Upper respiratory tract infectionInfections and infestations7/1194/11911/178
Infusion related reactionInjury, poisoning and procedural complications3/1197/1192/178

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Anti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mgTotal
<=18 years00000
Between 18 and 65 years81762221200
>=65 years14192338
Sex: Female, Male
Sex: Female, Male(Participants)Anti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mgTotal
Female49601719145
Male46357593
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Anti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mgTotal
Hispanic or Latino683118
Not Hispanic or Latino89862123219
Unknown or Not Reported01001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Anti-AChR-Ab+: PlaceboAnti-AChR-Ab+: Inebilizumab 300 mgAnti-MuSK-Ab+: PlaceboAnti-MuSK-Ab+: Inebilizumab 300 mgTotal
American Indian or Alaska Native10001
Asian40311515101
Other11002
Black or African American22105
White496089126
Moore than one race00000
Unknown or not reported21003
08

Study locations

104 sites
  • Viela Bio Investigative Site - 1015
    Orange, California 92868, United States
  • Viela Bio Investigative Site - 1002
    New Haven, Connecticut 06519, United States
  • Viela Bio Investigative Center - 1024
    Washington D.C., District of Columbia 20010, United States
  • Viela Bio Investigative Site - 1005
    Tampa, Florida 33612, United States
  • Viela Bio Investigative Site - 1012
    Kansas City, Kansas 66160, United States
  • Viela Bio Investigative Site - 1018
    Charlotte, North Carolina 28203, United States
  • Viela Bio Investigative Site - 1025
    Canton, Ohio 44718, United States
  • Viela Bio Investigative Site - 1001
    Cincinnati, Ohio 45219, United States
  • Viela Bio Investigative Site - 1009
    Columbus, Ohio 43210, United States
  • Viela Bio Investigative Site - 1008
    Pittsburgh, Pennsylvania 15212, United States
  • Viela Bio Investigative Site - 1019
    Austin, Texas 78759, United States
  • Viela Bio Investigative Site - 1003
    Houston, Texas 77030, United States
  • Viela Bio Investigative Site - 1014
    San Antonio, Texas 78229, United States
  • Viela Bio Investigative Site - 1017
    Salt Lake City, Utah 84132, United States
  • Viela Bio Investigative Site - 1004
    Burlington, Vermont 05401, United States
  • Viela Bio Investigative Site - 1006
    Richmond, Virginia 23298, United States
  • Viela Bio Investigative Site - 2001
    Buenos Aires, C1023AAB, Argentina
  • VielaBio Investigative Site - 2002
    Buenos Aires, C1199ABB, Argentina
  • Viela Bio Investigative Site - 2003
    Buenos Aires, C1221ADC, Argentina
  • Viela Bio Investigative Site - 5203
    Grodno, 230030, Belarus
  • Viela Bio Investigative Site - 5204
    Minsk, 220114, Belarus
  • Viela Bio Investigative Site - 5201
    Vitebsk, 210009, Belarus
  • VielaBio Investigative Site - 2201
    Porto Alegre, 90035-001, Brazil
  • VielaBio Investigative Site - 2203
    Porto Alegre, 90840-440, Brazil
  • VielaBio Investigative Site - 2207
    Ribeirão Preto, 14051-140, Brazil
  • VielaBio Investigative Site - 2206
    São Paulo, 01228-000, Brazil
  • Viela Bio Investigative Site - 2205
    São Paulo, 08270-120, Brazil
  • Viela Bio Investigative Site - 1102
    Toronto, Ontario M5G 2C4, Canada
  • Viela Bio Investigative Site - 1101
    Montreal, Quebec H2X 3J4, Canada
  • Viela Bio Investigative Site - 1103
    Montreal, Quebec H3A 2B4, Canada
  • Viela Bio Investigative Site 4009
    Beijing, 100029, China
  • Viela Bio Investigative Site - 4007
    Beijing, 100053, China
  • Viela Bio Investigative Site 4003
    Beijing, 100070, China
  • Viela Bio Investigative Site - 4005
    Guiyang, 550004, China
  • Viela Bio Investigative site 4010
    Hunan, 410008, China
  • Viela Bio Investigative Site - 4011
    Jinan, 250012, China
  • Viela Bio Investigative Site - 4006
    Shanghai, 201107, China
  • Viela Bio Investigative Site - 4008
    Suzhou, 215006, China
  • Viela Bio Investigative Site - 4004
    Tianjin, 300052, China
  • Viela Bio Investigative Site 4012
    Xi'an, 710038, China
  • Viela Bio Investigative Site - 5601
    Copenhagen, 2100, Denmark
  • Viela Bio Investigative Site - 3003
    Lille, 59037, France
  • Viela Bio Investigative Site - 3001
    Nice, 06001, France
  • Viela Bio Investigative Site - 3002
    Strasbourg, 67098, France
  • VielaBio Investigative Site - 3101
    Essen, 45122, Germany
  • Viela Bio Investigative Site - 4107
    Nagpur, Maharashtra 440003, India
  • Viela Bio Investigative Site - 4113
    Nagpur, Maharashtra 440012, India
  • Viela Bio Investigative Site - 4112
    Hyderabad, Telangana 500082, India
  • Viela Bio Investigative Site - 4104
    Bangalore, 560002, India
  • Viela Bio investigative Site - 4105
    Lucknow, 226014, India
  • Viela Bio Investigative Site - 4103
    Manipal, 576104, India
  • Viela Bio Investigative Site - 4102
    Nashik, 422002, India
  • Viela Bio Investigative Site - 4109
    Pune, 411004, India
  • Viela Bio Investigative Site - 4101
    Surat, 395002, India
  • Viela Bio Investigative Site - 3204
    Milan, 20122, Italy
  • Viela Bio Investigative Site - 3203
    Milan, 20133, Italy
  • Viela Bio Investigative Site - 3201
    Pavia, 27100, Italy
  • Viela Bio Investigative Site - 3202
    Rome, 168, Italy
  • Viela Bio Investigative Site - 4402
    Chiba, 260-8677, Japan
  • Viela Bio Investigative Site - 4410
    Chiba, 286-8520, Japan
  • Viela Bio Investigative Site - 4401
    Fukuoka, 025-0082, Japan
  • Viela Bio Investigative Site 4409
    Fukuoka, 812-8582, Japan
  • VielaBio Investigative Site - 4408
    Hokkaido, 041-8680, Japan
  • Viela Bio Investigative Site - 4406
    Hyōgo, 663-8501, Japan
  • Viela Bio Investigative Site 4405
    Miyagi, 983-8520, Japan
  • Viela Bio Investigative Site - 4413
    Moriguchi, 570-8507, Japan
  • VielaBio Investigative Site - 4407
    Morioka, 020-8505, Japan
  • Viela Bio Investigative Site - 4404
    Saitama, 350-8550, Japan
  • Viela Bio Investigative Site - 3302
    Katowice, 40-635, Poland
  • Viela Bio Investigative Site - 3303
    Katowice, 40-752, Poland
  • Viela Bio Investigative Site - 3301
    Krakow, 31-505, Poland
  • Med Polonia Sp. z o.o - 3311
    Poznan, 60-693, Poland
  • Viela Bio Investigative Site - 3310
    Warsaw, 01-868, Poland
  • Viela Bio Investigative Site - 5313
    Barnaul, Altayskiy Kray 656043, Russia
  • Viela Bio Investigative Site - 5303
    Barnaul, 656045, Russia
  • Viela Bio Investigative Site - 5302
    Nizhny Novgorod, 603126, Russia
  • Viela Bio Investigative Site - 5304
    Novosibirsk, 630087, Russia
  • Viela Bio Investigative Site - 5311
    Rostov-on-Don, 344015, Russia
  • Viela Bio Investigative Site - 5309
    Rostov-on-Don, 344022, Russia
  • Viela Bio Investigative Site - 5308
    Saint Petersburg, 197110, Russia
  • Viela Bio Investigative Site - 5305
    Samara, 443095, Russia
  • Viela Bio Investigative Site - 5312
    Ufa, 450083, Russia
  • Viela Bio Investigative Site - 4202
    Seoul, 3722, South Korea
  • Viela Bio Investigative Site - 4203
    Seoul, 5030, South Korea
  • Viela Bio Investigative Site - 4201
    Seoul, 6351, South Korea
  • Viela Bio Investigative Site - 3403
    Badalona, 8916, Spain
  • Viela Bio Investigative Site - 3402
    Barcelona, 8003, Spain
  • Viela Bio Investigative Site - 3404
    Córdoba, 14004, Spain
  • Viela Bio investigative Site - 4605
    Kaohsiung City, 83301, Taiwan
  • Viela Bio Investigative Site 4608
    New Taipei City, 235, Taiwan
  • Viela Bio Investigative Site - 4606
    Tainan, 704, Taiwan
  • Viela Bio Investigative Site - 4604
    Taipei, 10002, Taiwan
  • Viela Bio Investigative Site - 4603
    Taipei, 111, Taiwan
  • Viela Bio Investigative Site -4607
    Taipei, 11217, Taiwan
  • Viela Bio Investigative Site - 4602
    Taoyuan City, 333, Taiwan
  • Viela Bio Investigative Site - 3903
    Ankara, 6230, Turkey (Türkiye)
  • Viela Bio Investigative Site - 3901
    Izmir, 35100, Turkey (Türkiye)
  • Viela Bio Investigative Site - 3902
    Izmir, 35330, Turkey (Türkiye)
  • Viela Bio Investigative Site - 3905
    Kocaeli, 41380, Turkey (Türkiye)
  • Viela Bio Investigative Site - 5103
    Dnipro, 49005, Ukraine

Showing the first 100 of 104 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Nowak RJ, Benatar M, Ciafaloni E, Howard JF Jr, Leite MI, Utsugisawa K, Vissing J, Rojavin M, Li Q, Tang F, Wu Y, Rampal N, Cheng S; MINT Investigators. A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis. N Engl J Med. 2025 Jun 19;392(23):2309-2320. doi: 10.1056/NEJMoa2501561. Epub 2025 Apr 8. PubMed 40202593 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in May 2024, 43 months.

Results were first posted in Mar 2026, 1 year 9 months after primary completion. A results delay was requested in Feb 2025.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 43 months is above that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2020
First posted
Aug 24, 2020
StartActual
Oct 15, 2020
Primary completionActual
May 28, 2024
CompletionEst.
Jun 7, 2029
Results delay requested
Feb 14, 2025
Results first posted
Mar 10, 2026
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04524273
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 24, 2020
Start date
Oct 15, 2020
Primary completion
May 28, 2024
Completion
Jun 7, 2029 (estimated)
Results posted
Mar 10, 2026
Last update
May 15, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion